ELV · Elevance Health Inc.

conf 2/10 partial

enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:5 · business_impact:8 · disruption:0 · commitment:6 · confirmation:0

Enthusiasm latest 8 / prev 4 (rising)

The AI thesis rose sharply in Q1 FY2026: management moved from general advanced-analytics and HealthOS language to explicit enterprise AI scaling across clinical, operational, administrative, member-navigation, matching, prior authorization, and associate-productivity workflows. Credibility is moderate because management gave real deployment metrics and some operational impact claims, but most financial linkage remains qualitative rather than directly tied to revenue, margin, or EPS.

Grounded on actual base — revenue $199.1B · net income $5.7B · net margin 2.8% · diluted EPS 25.12

These are next-fiscal-year annual uplift estimates, not next-quarter numbers.

Aggregate next-FY est. rev uplift: % · next-FY EPS uplift: % · vs analysts: unclear · priced in: medium · confidence: 2/10

Assumptions: Tax rate 21%; default incremental net margin = company net margin (2.843%), would only bind if a revenue claim existed. EPS sized against the ADJUSTED basis consensus uses (~$6.0B NI / ~$26.85 FY26 EPS), NOT the depressed GAAP $5.662B / 2.843% margin which would turn any saving into a meaningless huge %. The >$1B figure is investment spend (near-term drag if expensed), not a benefit; phasing not disclosed. ~221.8M shares. ELV is a pure adopter (health-insurance payer), no supplier side.

Top line: No quantifiable topline AI impact. Every AI disclosure is a reach/engagement/operational metric (22M members on the assistant, >20% / >4.4M matched, 500+ data points, 60k associates, 80% real-time PA) with NO revenue-per-user, take-rate, or incremental-bookings figure. The only dollar, >$1B, is investment (>0.502% of revenue), not incremental revenue. Nothing maps to a revenue line -> est_rev_uplift_pct = null.

Bottom line: Also unquantifiable from disclosure. The plausibly bottom-line items — ~70% prior-auth denial reduction, 80% real-time PA by 2027, 60k AI-enabled associates — are admin-efficiency claims with NO disclosed dollar base (prior-auth ops are an undisclosed slice of the ~$21B adjusted opex implied by the 10.6% expense-ratio guide). The only hard dollar is >$1B of investment spend, a near-term drag (~<0.4%/yr of revenue if expensed), not a benefit. With ELV's thin 2.843% net margin, even modest savings would create large EPS %s, so EPS uplift is left null rather than overstated. est_eps_uplift_pct = null.

Consensus embeds an earnings recovery: FY26 EPS $26.85 -> FY27 $29.24 = +8.9%, below management's 'at least 12% adjusted EPS growth in 2027 off the 2026 baseline.' A 12% target off FY26 consensus implies ~$30.07, ~$0.83 (~2.8%, ~$184.8M on 221.8M shares) above consensus — and the 10.6% ±50bp opex-ratio guide is where AI/digital efficiency would surface. So a consensus-vs-guidance gap exists, but management attributes it to the whole diversified platform (Carelon clinical capabilities + AI + simplification), not AI specifically, with zero AI-attributable dollars. The AI-only contribution cannot be separated from the broader earnings-power story, and the opex-discipline guide likely already absorbs most AI efficiency -> medium priced-in, AI-specific impact unclear.

• we are already seeing tangible results.
• When we look at where we've already invested, our AI-enabled virtual assistant, I think, is a really good example.
• We already have 22 million commercial members on that using it regularly, and it's helping people get answers fast with less friction.
• More than 20% of our members have already connected and are finding the right providers.
• More than 60,000 already have access to it.

• we are embedding and scaling AI across clinical, operational and administrative workflows where it can have direct measurable impact
• These capabilities are improving how we engage members and how we manage costs.
• we're using predictive analytics to identify members at risk of substance use disorder before adverse events occur.
• Using AI and advanced analytics, we are identifying high-risk members earlier and engaging them through coordinated whole-person care.
• we're investing more than $1 billion in digital and AI-enabled capabilities to support that strategy.
• We're using it right now in our prior authorization commitments.

• Further, we are investing to scale AI across our enterprise, which will enable earlier identification of a member's health needs, guide them to more effective and affordable care and reduce administrative complexity, strengthening both outcomes and long-term performance.
• the focused investments we're making in artificial intelligence and Carelon's clinical capabilities will improve how we operate, strengthen our earnings power and better position the enterprise for long-term growth.
• We see this technology and AI reducing those denials by more than almost 70% and it eliminates a lot of the need for follow-up and back and forth.
• we expect to return to at least 12% adjusted EPS growth in 2027 off our ending 2026 earnings baseline supported by the earnings power of our diversified platform.
• Our adjusted operating expense ratio is expected to be 10.6%, plus or minus 50 basis points, as we maintain operational discipline while investing to scale Carillon, embed AI-enabled and digital capabilities, and simplify the member experience.

50/100 track record   mixed  6 calls reviewed

Elevance leans heavily on AI/analytics language (HealthOS, intelligent clinical assist, predictive analytics, AI virtual assistant) but rarely attaches hard numbers-plus-dates; the few quantified items are mostly forward 2027 targets that aren't yet judgeable, plus a 10M-member virtual-assistant year-end goal that was quietly not reconfirmed, leaving a thin and forward-dated track record.

Est. revisions rising  ·  Fwd P/E 13.0  ·  EV/Sales 0.5x

AI claim maps to Health Benefits Segment, Carelon Services Segment

AI enthusiasm across 6 calls — trend ↗ rising

AI evolved from digital personalization and data-sharing into explicit enterprise-scale clinical, operational, predictive analytics, and automation initiatives tied to costs and outcomes.

• 2026-05-19 · AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers
• 2026-03-20 · Elevance Health, Inc. (NYSE:ELV) Receives Average Rating of “Moderate Buy” from Brokerages

8/10 qualitative impact   material  medium-term · mixed evidence

Where AI matters: medical-cost management, member navigation, prior authorization, admin automation

Elevance is applying AI directly to high-leverage managed-care workflows: earlier risk identification, provider matching, virtual assistance, prior authorization automation, and associate productivity, with deployment scale across 22M commercial members and 60k associates. The upside is credible but still mostly operational because management has not tied these metrics to explicit revenue, MLR, opex, or EPS dollars.

Caveats: Financial benefits are not separately quantified and may be absorbed by reinvestment or medical-cost inflation; AI use in prior authorization and clinical decisions carries regulatory, litigation, and reputational risk; Execution credibility is mixed, with some prior quantified milestones not clearly reconfirmed; Savings depend on adoption by members, providers, and internal workflows, not just tool deployment

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 2/10

AI does not commoditize the core health-insurance model of underwriting, risk pooling, network contracting, regulated plan administration, and medical-cost management. It may pressure some administrative or PBM-style opacity over time, but for Elevance the dominant effect is automation and better care steering rather than revenue-model deflation.

option liquidity: good

proxy inputs — dollar-ADV $728M · beta 0.671 · px $389.03

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.